Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 4.31%
- Poor long term growth as Net Sales has grown by an annual rate of -5.29% and Operating profit at -28.77% over the last 5 years
- The company is Net-Debt Free
2
With ROE of -4.22%, it has a Very Expensive valuation with a 0.71 Price to Book Value
3
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
ILS 169 Million ()
NA (Loss Making)
NA
0.00%
-0.13
-0.14%
0.62
Revenue and Profits:
Net Sales:
14 Million
(Quarterly Results - Dec 2025)
Net Profit:
13 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.72%
0%
-6.72%
6 Months
-8.34%
0%
-8.34%
1 Year
-24.13%
0%
-24.13%
2 Years
-56.58%
0%
-56.58%
3 Years
-14.31%
0%
-14.31%
4 Years
-19.68%
0%
-19.68%
5 Years
-26.47%
0%
-26.47%
Golden House Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-5.29%
EBIT Growth (5y)
-28.77%
EBIT to Interest (avg)
0.77
Debt to EBITDA (avg)
4.78
Net Debt to Equity (avg)
-0.85
Sales to Capital Employed (avg)
0.11
Tax Ratio
15.27%
Dividend Payout Ratio
2,716.64%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.31%
ROE (avg)
3.34%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.71
EV to EBIT
41.19
EV to EBITDA
25.44
EV to Capital Employed
0.67
EV to Sales
3.28
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1.62%
ROE (Latest)
-4.22%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
14.10
12.40
13.71%
Operating Profit (PBDIT) excl Other Income
3.70
2.40
54.17%
Interest
0.80
1.60
-50.00%
Exceptional Items
8.50
-0.30
2,933.33%
Consolidate Net Profit
13.20
-7.60
273.68%
Operating Profit Margin (Excl OI)
245.00%
177.70%
6.73%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 13.71% vs 11.71% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 273.68% vs -985.71% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
48.90
39.80
22.86%
Operating Profit (PBDIT) excl Other Income
7.30
3.80
92.11%
Interest
3.40
6.90
-50.72%
Exceptional Items
7.50
2.20
240.91%
Consolidate Net Profit
7.20
4.10
75.61%
Operating Profit Margin (Excl OI)
132.30%
71.40%
6.09%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 22.86% vs -34.86% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 75.61% vs -74.53% in Dec 2024






